Compare CRGO & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRGO | XBIT |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7M | 69.8M |
| IPO Year | 2022 | 2015 |
| Metric | CRGO | XBIT |
|---|---|---|
| Price | $0.80 | $2.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.80 | N/A |
| AVG Volume (30 Days) | ★ 74.3K | 32.2K |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.32 | N/A |
| Revenue Next Year | $10.35 | $30.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $2.09 |
| 52 Week High | $4.24 | $3.44 |
| Indicator | CRGO | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 29.59 | 51.97 |
| Support Level | N/A | $2.15 |
| Resistance Level | $1.43 | $2.46 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 2.76 | 45.00 |
Freightos Ltd operates as a vendor-neutral booking and payment platform for international freight. Its platform supports supply chain efficiency and agility by enabling real-time procurement of ocean and air shipping across more than ten thousand importers/exporters, thousands of forwarders, and dozens of airlines and ocean carriers. The company operates in two segments: the Platform segment and the Solutions segment. The majority of the revenue is derived from the Solutions segment, which provides software tools and data to help industry participants automate their pricing, sales, and procurement processes. Geographically, it generates the maximum revenue from Europe, and the rest from the United States, Hong Kong and Others.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.